B Braun Medical has been granted 510(k) clearance from the US Food and Drug Administration (FDA) for its Introcan Safety 2 Deep Access IV Catheter, which is designed to access deeper veins in patients with difficult vascular access.

The German device company claims that the Introcan Safety 2 Deep Access IV catheter is a merger of its previous offerings, the Introcan Safety 2 Multi-Access and the Introcan Safety Deep Access catheters. The said research published in the Annals of Emergency Medicine found that B. Braun’s catheters can drive its average use time before being replaced from 3.8 days to 5.7 days.

Additionally, B Braun claims that its multi-access blood control hub, part of the Introcan Safety 2 Deep Access catheter, is designed to minimise blood exposure and reduce the need for cleanup throughout IV therapy.

Chad Laity, director of marketing for vascular access and IV systems at B Braun, said: “We are excited to broaden our Introcan Safety 2 IV Catheter portfolio, allowing our customers to benefit from passive safety and blood exposure protection with deep access technology.

“By offering a reliable solution for challenging cases, we aim to help improve patient outcomes and reduce the need for more complex procedures."

Now, B Braun says they will be unveiling the device as part of the Association for Vascular Access (AVA) Scientific Meeting in Denver, Colorado, from 28 to 30 September, where they will be demonstrating how the device can fit into a clinician's current workflow.

Elsewhere in the field of catheter technology, Jupiter Endovascular has treated the first two patients in the SPIRARE I study, utilising its Vertex pulmonary embolectomy (PE) system. Meanwhile, Toro Neurovascular announced the successful treatment of the first patient in a first-in-man clinical trial of its Toro 88 SuperBore Aspiration Catheter for acute ischaemic stroke treatment in Japan.